EGFR and neoplasm: Intravenously applied CAR-T cells, that were designed to target an epitope of EGFRvIII and a form of EGFR expressed on tumor cells but not on EGFR-expressing normal cells, were able to effectively lyse EGFRvIII- or EGFR-overexpressing tumor cells in a subcutaneous xenograft mouse model injected with EGFR-expressing tumor cells of the U87 and U251 cell lines.